Table 4.

Clinical Assessments At 12 Months In Intention To Treat Population. Estimated treatment effects are shown between trial arms.

Assessment	Intensive Management	Standard Care	Linear Regression*				Mixed Effect Models
	N = 168	N = 167	Unadjusted	P-value	Adjusted	P-value	Unadjusted	P-value	Adjusted	P-value
	Mean (SE)	Mean (SE)	Coefficients		Coefficient		Coefficients		Coefficient
			(95% CI)		(95% CI)		(95% CI)		(95% CI)
DAS28-ESR	3.4 (0.1)	3.8 (0.1)	−0.6 (−0.9, −0.3)	<0.001	−0.5 (−0.8, −0.2)	0.001	−0.4 (−0.7, −0.2)	0.001	−0.4 (−0.6, −0.1)	0.003
Tender Joints	7.5 (0.7)	10.8 (0.8)	−2.4 (−4.4, −0.3)	0.023	−2.7 (−4.5, −0.8)	0.004	−1.4 (−3.4, 0.7)	0.187	−1.7 (−3.5, 0.2)	0.076
Swollen joints	3.5 (0.4)	4.9 (0.5)	−1.9 (−3.0, −0.7)	0.002	−1.6 (−2.7, −0.5)	0.004	−1.5 (−2.6, −0.5)	0.005	−1.3 (−2.3, −0.4)	0.006
ESR	17 (1)	15 (1)	−1.5 (−3.9, 1.0)	0.239	−1.1 (−3.4, 1.1)	0.329	−1.1 (−3.2, 1.0)	0.312	−0.7 (−2.7, 1.2)	0.463
CRP	9 (2)	7 (1)	0.9 (−2.6, 4.4)	0.628	1.5 (−1.8, 4.7)	0.372	0.6 (−2.0, 3.1)	0.666	1.3 (−0.9, 3.5)	0.239
Assessor Global	23 (2)	31 (2)	−6 (−12, −0.2)	0.043	−8 (−13, −3)	0.003	−4 (−9, 2)	0.169	−5 (−10, −1)	0.015
Patient Global	29 (2)	41 (2)	−9 (−15, −2)	0.010	−11 (−17, −6)	<0.001	−6 (−12, −1)	0.026	−9 (−14, −4)	<0.001
Fatigue	40 (2)	50 (2)	−18 (−24, −11)	<0.001	−15 (−21, −9)	<0.001	−16 (−21, −10)	<0.001	−13 (−18, −8)	<0.001
Pain	28 (2)	37 (2)	−6.5 (−13., 0.4)	0.064	−8.4 (−15, −2.3)	0.007	−4 (−11, 2)	0.161	−6 (−12, −1)	0.015
HAQ	1.0 (0.1)	1.1 (0.1)	−0.1 (−0.2, 0.0)	0.055	−0.1 (−0.2, 0.0)	0.046	−0.1 (−0.1, 0.0)	0.136	−0.1 (−0.2, 0.0)	0.137
EQ5D-5L	0.76 (0.02)	0.72 (0.02)	0.02 (−0.02, 0.06)	0.248	0.03 (−0.01, 0.07)	0.078	0.02 (−0.01, 0.05)	0.275	0.02 (−0.01, 0.05)	0.121
Larsen score	13 (1)	10 (1)	0.5 (−0.1, 1.0)	0.095	0.4 (−0.2, 0.9)	0.175	–	–	–	–

^⁎Change from baseline analysed and adjustments made for demographics (age, gender, ethnicity, disease duration) design factors (NHS region) and baseline score; standard of care arm was the reference group; SE =standard errors; CI= 95% confidence Intervals.